Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Elanco (ELAN)

Elanco Reports Third Quarter 2026 Results and Raises Full-Year Guidance

Positive Impact 4 of 5 earnings

Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.

Key points

  • Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
  • Reported net income was $18 million, while adjusted EPS was $0.27.
  • Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
  • Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.

The filing

CompanyElanco (ELAN)
Form8-K, current report
Filed with the SECNov 6, 2026, 6:27 AM ET
Accession number0001739104-26-000054

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 6, 2026, 9:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.